COMMUNIQUÉS West-GlobeNewswire

Integra LifeSciences Reports Second Quarter 2025 Financial Results
31/07/2025
PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending [...]
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
31/07/2025
Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting toxicities [...]
SAFE - Informations complémentaires concernant le report de publication des résultats annuels 2024
31/07/2025
Informations complémentaires concernant le report de publication des résultats annuels 2024 Fleurieux-sur-l’Arbresle – France – 31 juillet 2025 à 12h - Safe (FR001400RKU0 – ALSAF) annonce qu’elle devrait disposer de l’ [...]
ICPO and SBMN deepen their collaboration to advance Clinical Theranostics Centers of Excellence in Brazil
31/07/2025
ICPO accreditation following international theranostics guidelines and ICPO Academy for Theranostics will fuel the partnership right from start. July 31, 2025 – Wiesbaden, Germany, and Sao Paulo, Brazil. During the [...]
Teleflex Reports Second Quarter Financial Results and Full Year 2025 Outlook
31/07/2025
WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 29, 2025. Second quarter financial summary GAAP revenue [...]
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
31/07/2025
$12.5 million in second quarter PYRUKYND ® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable securities PYRUKYND sNDA for thalassemia under active review, [...]
Teleflex Announces Quarterly Dividend
31/07/2025
WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The [...]
XORTX Announces USD $114,500 Private Placement
31/07/2025
CALGARY, Alberta, July 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing [...]
Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
31/07/2025
Granted patents provide broad composition, formulation, and method of use protection across key global markets including use of MDNA11 in combination with checkpoint inhibitors and a novel formulation of bizaxofusp [...]
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025
31/07/2025
BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics [...]
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
31/07/2025
Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold ® Q2 Revenue of $128.9M, up 12% at CER Pombiliti ® + Opfolda ® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including GAAP [...]
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
31/07/2025
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and [...]
Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
31/07/2025
CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
31/07/2025
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of [...]
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
31/07/2025
– Initial interim safety, tolerability, biomarker, and preliminary efficacy data expected in Q1 2026 – MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a [...]
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
31/07/2025
Received U.S. FDA approval for EMPAVELI ® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGN Announced capped royalty purchase agreement with Sobi under which Apellis receives up [...]
FOXO TECHNOLOGIES INC. ANNOUNCES LICENSE RENEWAL AND PROVIDES OPERATIONAL UPDATE FOR MYRTLE RECOVERY CENTERS, INC.
31/07/2025
WEST PALM BEACH, FLORIDA, July 31, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies, Inc., (NYSE American: FOXO) (“FOXO” or the “ Company ”) today announced that its behavioral health subsidiary, Myrtle Recovery Centers, Inc [...]
Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
31/07/2025
WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a [...]
InflaRx to Report Second Quarter 2025 Results on August 7, 2025
31/07/2025
JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company [...]

Pages